Abstract
We analysed factors predicting early treatment failure (ETF), after first-line therapy for light-chain amyloidosis (AL). AL amyloidosis patients seen at Mayo Clinic within 90 days of diagnosis, from 2006 to 2015, excluding those who died within 3 months of initial therapy, were analysed retrospectively. ETF was defined as progression requiring treatment change or death within 12 (ETF12) or 24 (ETF24) months of first-line treatment. Non-ETF included those with a follow-up of more than 12 or 24 months who had progression beyond 12 or 24 months. A total of 724 patients met the study criteria; 244 (33.7%) had ETF12 and 388 (53.6%) had ETF24. Patients with ETF12 were older (64.1 vs. 62.2 years) with higher prevalence of cardiac (81 vs. 64.1%) and multi-organ involvement (67.2 vs. 45.4%) and higher proportion of patients with t(11; 14) (58.5 vs. 44.3%) or in higher Mayo 2012 stage (58.5 vs. 41.1%).The median follow-up was 5.4 years from start of initial therapy. In multivariate analysis, presence of t(11; 14) and non-incorporation of autologous transplant in initial therapy are significant predictors of ETF12 (p =.01and p =.003) and ETF24 (p =.0001 and p =.005) while Mayo stage is predictive of ETF24 (p =.002), but not ETF12.
Original language | English (US) |
---|---|
Pages (from-to) | 183-188 |
Number of pages | 6 |
Journal | Amyloid |
Volume | 24 |
Issue number | 3 |
DOIs | |
State | Published - Jul 3 2017 |
Keywords
- Predictors
- amyloidosis
- early death
- refractory
- relapse
ASJC Scopus subject areas
- Internal Medicine